T he regulated shedding of extracellular vesicles (EVs) is now understood to be an important means of intercellular communication [1] [2] [3] . Among these, microvesicles released from tumour cells, often called tumour-derived microvesicles (TMVs), have emerged as crucial participants in tumour pathogenesis, metastasis and communication [4] [5] [6] [7] . Unlike another class of EVs, tumourderived exosomes, TMVs are generated through direct budding from the plasma membrane into the extracellular space, where they can interact with and influence recipient cells within the local tumour microenvironment or at distal sites [2] [3] [4] 8 . Direct release into the extracellular space allows for TMV detection and isolation from peripheral bodily fluids 5, 9 . Tumour-derived-microvesicle biogenesis is tightly regulated with cellular control exerted over the inclusion of specific cargo and fission events that release the vesicle from the originating cell 1, 5 . It is now known that TMV shedding is at least partly regulated by signalling pathways governed by the activation of small GTPases, including ADP-ribosylation factor 6 (ARF6), RhoA and Rab22A 3, 4, 6, 8, 10 . Budding of TMVs converges on the activation of intrinsic contractile machinery to facilitate the fission and release of mature TMVs 6, 8 . Although some cargo originates from the recycling of endosomal membranes, certain other endosomal components are excluded from shed TMVs 8 , thus highlighting the selective recruitment of TMV cargo. For example, association between MT1-MMP and the vSNARE VAMP-3 was shown to direct the trafficking of protease cargo through the endosomal system to sites of TMV formation 5 . In addition, studies have shown that the arrestin 1 domain-containing protein 1 (ARRDC1) recruits the ESCRT-I subunit TSG101 to the plasma membrane, which results in the release of small microvesicles containing TSG101, ARRDC1 and other cellular proteins [11] [12] [13] . Further study of the regulators of TMV cargo trafficking, delivery and inclusion/exclusion is necessary to advance our understanding of TMV biogenesis.
Many functional consequences of TMV release stem from their diverse bioactive cargo, which includes proteases, cell-surface receptors, nucleic acids and active lipids 4, 5, [14] [15] [16] . Horizontal transfer of bioactive cargoes represents a mechanism through which these vesicles can alter recipient cells 14, [16] [17] [18] [19] . Among the nucleic acids capable of altering the gene expression of the recipient cell, small RNAs-especially microRNAs (miRNAs)-are increasingly important. The deregulation of miRNAs has been documented in multiple cancers, where they are known to target tumour suppressors and related proteins, resulting in poor patient outcomes [20] [21] [22] [23] [24] . MicroRNAs represent the dominant class of small RNAs that have evolved to suppress unwanted genetic material and transcripts in somatic tissues. Their processing begins with the transcription of primary miRNA sequences that contain one or more hairpin structures and a terminal loop. Before nuclear export, primary miRNAs are processed to pre-miRNA by the microprocessor complex containing DGCR8 and Drosha. Pre-miRNA is exported from the nucleus by the importin β-like nuclear export receptor Exportin-5 together with Ran-GTP 25, 26 , where it is cleaved into an approximately 22-nt miRNA duplex by Dicer before one of the strands is loaded into the RNA-induced silencing complex together with a member of the Argonaute family of proteins 27 . In general, the RNA cargo contained within EVs reflects the levels and types of cytoplasmic content, is determined by the mode of EV biogenesis, and the type and physiologic state of the releasing cell 1, 28 . Since the identification of miRNAs within EVs, various mechanisms have been proposed for their selection into exosomes. RNAbinding proteins, Y-box protein 1 and sumoylated hnRNPA2B1 are reported to bind miRNAs at specific sequence motifs and mediate their trafficking to exosomes 29, 30 . Overexpression of nSMase2 has been shown to increase exosomal miRNAs 31, 32 . Argonaute-2, a protein associated with the RNA-induced silencing complex machinery is thought to control the loading of miRNA in part through KRASdependent association of P-bodies with the cytoplasmic membrane of multi-vesicular bodies [33] [34] [35] . Furthermore, the presence of premiRNA in exosomes along with CD43-mediated Dicer accumulation was previously reported to allow for pre-miRNA processing within exosomes 14 .
The mechanisms of pre-miRNA sorting and incorporation into TMVs is far less defined. Here we report that interaction between ARF6-GTP and Exportin-5 directs trafficking of a pre-miRNA Here we describe a molecular pathway for the delivery of microRNA (miRNA) cargo to nascent TMVs involving the dissociation of a pre-miRNA/Exportin-5 complex from Ran-GTP following nuclear export and its subsequent transfer to a cytoplasmic shuttle comprised of ARF6-GTP and GRP1. As such, ARF6 activation increases the pre-miRNA cargo contained within TMVs through a process that requires the casein kinase 2-mediated phosphorylation of RanGAP1. Furthermore, TMVs were found to contain pre-miRNA processing machinery including Dicer and Argonaute-2, which allow for cell-free pre-miRNA processing within shed vesicles. These findings offer cellular targets to block the loading and processing of pre-miRNAs within TMVs.
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complex to the sites of TMV biogenesis for inclusion as TMV cargo. This involves a hand off of pre-miRNA together with Exportin-5 from a Ran-GTP nuclear export complex to an ARF-guaninenucleotide-exchange-factor (GEF) scaffold that is essential for the ARF6-GTP-dependent delivery to TMVs. Disruption of the ability of Exportin-5 to interact with ARF6 results not only in the release of TMVs lacking Exportin-5 but a subsequent decrease in TMV miRNA cargo.
Results
Invasive tumour cells shed TMVs containing bioactive cargo, including miRNAs. Invasive tumour cells abundantly release multiple classes of EVs. Tumour-derived microvesicles represent a discrete class of EVs that is separated from another well characterized class, exosomes, by their size (Fig. 1a-c) , cargo content ( Supplementary Fig. 1a ) and distinct mode of biogenesis 8, 9 . Furthermore, TMVs are distinct from apoptotic bodies, lacking cleaved forms of poly (ADP-ribose) polymerase-1 or lamin A/C, both of which become highly enriched during apoptotic cell death ( Supplementary Fig. 1b) . Shed TMVs contain abundant bioactive cargos, including numerous protein cargos (Fig. 1d ) and nucleic acids 4 , which led us to examine their endogenous miRNA content. Through Bioanalyzer analysis we identified the small-sized RNA cargo-similar in size to pre-miRNA-within TMVs shed from invasive melanoma (LOX), breast (MDA-MB-231) or prostate (PC-3) tumour cells ( Fig. 1e and Supplementary Fig. 1c) . Analysis of the small RNA in TMVs at a higher resolution also indicated the inclusion of mature miRNA-sized RNA cargo within melanoma TMVs (Fig. 1f) . Small RNAs were subsequently isolated, sequenced and classified into small RNA pools including ribosomal RNA (rRNA), mitochondrial RNA (mtRNA), tRNA and miRNA (Fig. 1g) . The inclusion of miRNAs as TMV cargo is of particular interest as miRNAs released from tumour cells impinge on various aspects of cancer pathogenesis and progression [36] [37] [38] . ARF6 activation increases pre-miRNA and miRNA-related cargo in TMVs. Given that ARF6 facilitates both the delivery of TMV cargo and TMV release 8 , we examined whether activation of ARF6 led to changes in pre-miRNA and other miRNA-related cargo contained within shed TMVs. Expression of constitutively active ARF6-Q67L led to a fivefold increase in the levels of active ARF6 (Fig. 1h ) and a threefold increase in TMV shedding ( Supplementary Fig. 2a ). However, a comparison of the total small RNA per TMV showed no significant difference in ARF6-Q67L-expressing cells relative to parental control cells probably owing to the large proportion of non-miRNA content (Fig. 1i ). Yet, a significant increase in miRNA sequencing reads was observed with ARF6 activation (Fig. 1j) and a heat map of the 50 most abundant miRNAs found in TMVs revealed a global increase in TMV miRNA content following ARF6 activation, thus highlighting that the observed increase was not due to the enrichment of specific miRNAs ( Supplementary Fig. 2b ). These results were confirmed by quantitative PCR with reverse transcription (qRT-PCR) of TMV pre-miRNA and mature miRNA targets selected for their pro-tumour roles, including oncomiR miR-21 (ref. 39 ), tumour-suppressor-targeting miR-27a (ref. 40 ) and miR-100 (ref. 41 ), and pro-migratory miR-151 (ref. 42 ; Fig. 1k and Supplementary  Fig. 2c ). This increase in TMV miRNA content occurs despite a decrease in the cellular levels of these miRNAs with the activation of ARF6 ( Fig. 1l and Supplementary Fig. 2d ). Furthermore, as many biological effects of ARF6 are regulated through GDP/GTP cycling 43 , we confirmed these results using the fast-cycling mutant ARF6-T157N ( Supplementary Fig. 2e-g ).
Exportin-5 is an ARF6 binding partner. The increase in levels of TMV miRNA with ARF6 activation suggested the active inclusion of miRNA within TMVs. Interrogation of publicly available databases for possible modes by which ARF6 could facilitate miRNA trafficking revealed that the pre-miRNA transporter Exportin-5, a karyopherin known to transport pre-miRNA and RNA-binding proteins across the nuclear envelope 25, 26, 44 , was an ARF6 binding partner identified through a large-scale mapping of protein-protein interactions by mass spectrometry 45 . Furthermore, the Protein Interactions by Structural Matching (PRISM) algorithm 46 predicts a more favourable interaction between the Exportin-5/Ran-GTP/ dsRNA (PDB ID: 3A6P) complex and ARF6-GTP (PDB ID: 2J5X) than with ARF6-GDP (PDB ID: 1EOS; Fig. 2a,b and Supplementary  Fig. 3a ). This predicted interaction was validated through coimmunoprecipitation experiments ( Fig. 2c and Supplementary  Fig. 3b) . A GTP-dependent interaction between Exportin-5 and ARF6 was confirmed through co-precipitation using recombinant ARF6 incubated with GTP-γ-S or GDP (Fig. 2d) and through reciprocal co-immunoprecipitations from cells expressing dominant negative ARF6 (ARF6-T27N), which inhibits the interaction and reduces the amount of co-precipitating Exportin-5 ( Fig. 2e and Supplementary Fig. 3c ).
Immunofluorescence analysis of endogenous Exportin-5 showed abundant Exportin-5 in the nucleus together with a punctate cytoplasmic distribution consistent with chaperone protein cycling (Fig. 2f) . At higher magnifications, Exportin-5 could be identified within budding TMVs (Fig. 2g) , where it colocalizes with ARF6 ( Fig. 2h and Supplementary Fig. 3d ). A portion of Exportin-5 also co-localizes with ARF6 in areas closely apposed to the nucleus ( Supplementary Fig. 3e ). In addition, Exportin-5 was detected in isolated TMVs both by immunofluorescence ( Supplementary Fig. 3f ) and western blotting ( Fig. 2i and Supplementary Fig. 3g ). Together these results suggest that, through association with Exportin-5, pre-miRNA cargo may continue to traffic from the nucleus to the sites of TMV biogenesis for inclusion in shed TMVs. miRNA processing machinery is contained in shed TMVs. Exportin-5, Dicer and Argonaute-2 were identified within shed TMVs (Figs. 2i and 3a) and seemed to be enriched as a result of ARF6 activation (Fig. 3b,c and Supplementary Fig. 3h ), indicating an important role for ARF6-regulated endosomal membrane trafficking in delivering miRNA-related cargo to TMVs. Furthermore, the increase in mature TMV miRNA over time (Fig. 3d) suggests that increases in mature miRNA with ARF6 activation stem from an increased delivery of pre-miRNA. We then confirmed the inclusion of an Exportin-5/pre-miRNA/ARF6 complex in isolated TMVs (Fig. 3e) . Although exosomes have been shown to contain pre-miRNA processing machinery 14, 35 , its presence within TMVs was unknown. All of the above suggests that, although there may be unique regulators in each EV pathway, the inclusion of RNAinduced-silencing-complex machinery within shed TMVs indicates that this is probably a general phenomenon through which tumour cells modulate EV miRNA content.
CK2 facilitates cargo transfer from Ran to ARF6-GTP. Interphase cells maintain a strict Ran-GTP gradient across the nuclear envelope 47 . Following nuclear export, GTP hydrolysis on Ran is facilitated by the GTPase-activating protein RanGAP1, which liberates cargo for further transport 47 . Given the previously reported activation of casein kinase 2 (CK2) downstream of ARF6-GTP 48 and literature documenting that CK2-mediated 358 S phosphorylation of RanGAP1 allows RanGAP1 to form a stable ternary complex with Ran-GTP and RanBP1 49 , we examined the role of CK2 in the trafficking of Exportin-5 and pre-miRNA to shed TMVs. Treatment with 4,5,6,7-tetrabromobenzotriazole (TBB), a small molecule inhibitor of CK2, reduced the levels of Exportin-5 included as shed TMV cargo (Fig. 4a) along with a concomitant reduction in TMV and TMVs (LOX TMV) was separated by SDS-PAGE and the protein cargo was determined by western blotting. Blots are representative of n = 3 independent biological experiments. e, Agilent Bioanalyzer analysis using the RNA 6000 Nano kit of the TMV RNA content shows cargo corresponding in size to premiRNA (green bar). f, Higher resolution analysis of TMV small RNA using the Bioanalyzer small RNA 6-150 nt analysis kit shows a peak corresponding to mature miRNA (green bar). Representative images from n = 3 independent biological samples are shown in e,f. g, Bowtie analysis of the small-RNA content isolated from TMVs released from invasive tumour cell lines of melanoma, prostate and breast origin. For each cell type, n = 3 independent biological samples. h, ARF6 activity was measured using an MT2 ARF6-GTP-specific pulldown assay as described in Methods. Data are representative of n = 4 independent biological experiments. i, Analysis of the small-RNA content isolated from parental melanoma cells and those expressing constitutively active ARF6-GTP showed no difference in the quantity of detectable RNA with ARF6 activation. j, Sequencing analysis revealed a significant increase in the total read hits corresponding to miRNA following the expression of ARF6-Q67L. k, Analysis by qRT-PCR confirmed an increase in the pre-miRNA cargo content of the TMVs released by tumour cells of melanoma, ovarian (OvCar3) and breast origin. l, Analysis by qRT-PCR of the levels of total cell pre-miRNA with ARF6-Q67L expression. Data presented as the mean ± s.d. The statistical analysis for panels b-e were based on measurements obtained for n = 3 biological repeats. P values were determined by unpaired, two-tailed Student's t-tests between the control and treatment reactions for each independent experimental condition; P < 0.05 was considered significant. The unprocessed blot images are shown in Supplementary Fig. 7 and the statistical source data in Supplementary . c, Exportin-5 co-immunoprecipitates with ARF6, thus confirming the interaction predicted using PRISM. Total protein (200 μg) was subjected to immunoprecipitation as described in Methods. Antibody-bound protein was precipitated using Protein-G-conjugated Dynabeads before being resolved by SDS-PAGE and examined by western blotting. n = 3 biologically independent experiments. d, Exportin-5 preferentially binds active, GTP-bound ARF6 in vitro. Recombinant GST-ARF6 wild type (WT)-conjugated beads were incubated with lysates in the presence of 100 µM GTP-γ-S, 1 mM GDP or vehicle control for 60 min at 37 °C. The bound proteins were precipitated and separated by SDS-PAGE for western blotting (left) to examine the relative amounts of co-precipitating Exportin-5 (right). Data presented as the mean ± s.d. from n = 4 biologically independent experiments. P values were determined by one-way analysis of variance (ANOVA) with Sidak's correction for multiple comparisons; P < 0.05 was considered significant. e, Dominant negative ARF6-T27N inhibits Exportin-5 co-precipitation. Total protein (200 μg) from cells transiently expressing WT-ARF6 or ARF6-T27N was subjected to immunoprecipitation as described in Methods. The immunoprecipitated protein was resolved by SDS-PAGE and examined by western blotting as indicated. n = 3 biologically independent experiments. IB, immunoblot; IP, immunoprecipitation. f, Immunofluorescence analysis of endogenous Exportin-5 in invasive melanoma cells reveals intracellular distribution divided between nuclear and cytoplasmic pools. Scale bar, 15 μm. g, Analysis of Exportin-5 localization at a higher magnification indicating the inclusion of Exportin-5 in nascent TMVs at the cell periphery (arrows). Scale bar, 15 μm. The images in f,g represent n = 5 biologically independent experiments h, Endogenous Exportin-5 and ARF6 co-localize in nascent TMVs at the cell periphery (arrows). Scale bar, 25 μm; n = 3 biologically independent experiments. i, Western blot analysis of the cargo content of TMVs isolated from multiple invasive cell lines confirms the inclusion of Exportin-5 as TMV cargo. n = 3 biologically independent experiments. The unprocessed blot images are shown in Supplementary Fig. 7 and the statistical source data in Supplementary Table 1 .
Articles
NATuRE CEll BIoloGy pre-miRNA and miRNA cargo ( Fig. 4b and Supplementary Fig. 3i ). Treatment with TBB did not change the levels of ARF6 incorporated into shed TMVs (Fig. 4a ), which suggests a specific disruption in cargo delivery rather than a global reduction in TMV cargo. The intracellular distribution of Exportin-5 seemed to be perturbed following TBB treatment with CK2 inhibition, leading to reduced cytoplasmic Exportin-5 and a concomitant increase in nuclear signal (Fig. 4c,d ). Although we found no reduction in the overall cellular levels of Exportin-5 ( Fig. 4a and Supplementary Fig. 3j ), a reduced cytoplasmic pool and increased nuclear pool were confirmed by cell fractionation ( Supplementary Fig. 3k ). Similar results were obtained when CK2 was inhibited in the presence of constitutively active ARF6 ( , we examined the RanGAP1 phosphoserine levels in the presence of TBB. Treatment with TBB reduced the levels of RanGAP phosphoserine when the GAP was isolated using a green fluorescent protein (GFP) trap (Fig. 4h ). In addition, CK2 inhibition reduced the amount of both Ran and Exportin-5 that coprecipitated with ARF6 ( Fig. 4i ) and led to an increase in Ran and a decrease in ARF6 (Fig. 4j ) that co-precipitated with Exportin-5, suggesting that ARF6-mediated CK2 signalling facilitates the transfer of cargo from Ran to ARF6 for continued anterograde trafficking. Furthermore, examination of isolated TVM lysates revealed only small amounts of RanGAP and undetectable levels of Ran ( Supplementary Fig. 3n ). Together these results reveal that CK2 activation downstream of ARF6-GTP is required to facilitate Exportin-5 and pre-miRNA trafficking to TMVs.
ARF6-mediated Exportin-5 and miRNA trafficking requires the cytohesin family of ARF GEFs. ARF6 is activated by GEFs 50 and inhibition of the cytohesin family of ARF GEFs using the small molecule inhibitor SecinH3 blocks ARF6-regulated functions in invasive tumour cells 51 . We observed a marked loss of Exportin-5 signal in the cytoplasm following SecinH3 treatment (Fig. 5a ), which was confirmed by western blotting of fractionated cells ( Supplementary  Fig. 4a ). Biochemical analysis confirmed the loss of Exportin-5 cargo in TMVs isolated from SecinH3-treated cells (Fig. 5b) . Notably, cytohesin inhibition did not result in a significant reduction of the levels of total Exportin-5 protein ( Supplementary Fig. 4b ) or messenger RNA ( Supplementary Fig. 4c ). Chloroquine treatment was able to restore the cytoplasmic distribution of Exportin-5 ( Fig. 5c and Supplementary Fig. 4d ), suggesting that blockaded cargo that cannot be further trafficked is shunted to the lysosome for degradation. These results highlight the critical need for at least one functional member of the cytohesin family to facilitate anterograde Exportin-5 trafficking to the sites of TMV biogenesis.
To identify which cytohesin mediates Exportin-5 trafficking, we further interrogated publicly available databases and found that an ARF6-GTP and cytohesin 3 (GRP1) complex (PDB ID: 4KAX; Fig. 5d ) showed more favourable binding energies with Exportin-5 than the GTPase alone (Fig. 5e) . It is noteworthy that The Cancer ) of isolated TMVs maintained in cell-free conditions at 37 °C for the indicated times was analysed by qRT-PCR. The relative quantities of pre-miR-21 and mature miR-21 were measured as described in Methods. Data presented as the mean ± s.d. from n = 3 biologically independent experiments. e, TMVs were isolated from invasive melanoma cells and endogenous Exportin-5 was precipitated from 200 μg of input TMV protein. Co-precipitating RNA was examined by qRT-PCR and co-precipitating proteins by western blotting. Representative data from n = 3 biologically independent samples are shown. The unprocessed blot images are shown in Supplementary Fig. 7 ). Data presented as the mean ± s.d. from n = 3 biologically independent experiments. b, RNA isolated from TMVs with or without TBB treatment was analysed using qRT-PCR. CK2 inhibition results in a decrease of pre-miRNA within TMVs. Data presented as the mean ± s.d. for n = 3 biologically independent experiments. Statistical comparisons were made between the control and treatment reactions for each independent pre-miRNA. c, The intracellular distribution of Exportin-5 was examined by immunofluorescence in cells treated with TBB or DMSO vehicle control. Scale bars, 15 μm. Representative images from n = 3 biologically independent experiments are shown. d, Heat-map visualization of the Exportin-5 channel described in c. e, LOX cells expressing constitutively active ARF6-Q67L were treated with TBB to block CK2 activity. The localization of Exportin-5 was then examined by immunofluorescence microscopy. Representative images of n = 3 biologically independent experiments are shown. f, Heat-map visualization of the Exportin-5 channel described in e. g, Equal numbers of TMVs (1 × 10 8 ) were isolated from LOX ARF6-GTP cells and subjected to western blot analysis (left) to examine the levels of Exportin-5 contained as TMV cargo (right). Data presented as the mean ± s.d. from n = 3 biologically independent experiments. h, Melanoma cells expressing GFP-RanGAP were subjected to GFP-Trap and western blotting to examine the changes in the levels of phosphoserine (p-Ser) following treatment with TBB. Representative data from n = 3 biologically independent experiments are shown. i, ARF6 was immunoprecipitated from cells with CK2 inhibition. The amount of Exportin-5 and Ran that co-precipitated with the GTPase was then examined by western blotting. Representative images from n = 3 biologically independent experiments are shown. j, Exportin-5 was precipitated from cells treated with TBB and the levels of Ran and ARF6 that co-precipitated were subsequently examined by western blotting. Images are representative of n = 3 biologically independent repeats. The unprocessed blot images are shown in Supplementary Fig. 7 and the statistical source data in Supplementary Table 1 . P values were determined by unpaired two-tailed Student's t-tests; P < 0.05 was considered significant. ) of TMVs were isolated from control or GRP1-shRNA-treated LOX ARF6-Q67L cells and the lysates were analysed by western blotting as indicated. l, ARF6 was immunoprecipitated from LOX ARF6-Q67L cells with or without GRP1-shRNA. Co-precipitating proteins were examined by western blotting as indicated. Representative blots of n = 3 biologically independent experiments are shown for k,l. P values were calculated using unpaired two-tailed Student's t-tests; P < 0.05 was considered significant. The unprocessed blot images are shown in Supplementary Fig. 7 and the statistical source data in Supplementary Table 1 .
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Genome Atlas analysis 52 of GRP1 expression revealed a strong negative correlation between higher than median expression levels and poor survival (Supplementary Fig. 4e ). Similar results were not observed for other cytohesin family members ( Supplementary  Fig. 4f) . A similar correlation between GRP1 expression and poor survival was found in specific tumour types, including melanoma, ovarian cancer, breast cancer, squamous cell lung carcinoma and bladder cancer ( Supplementary Fig. 5a-e) , thus highlighting the importance of ARF activation during disease progression.
In light of the above, we identified an ARF6/Exportin-5/GRP1 complex through co-immunoprecipitation experiments ( Fig. 5f and Supplementary Fig. 6a) ; this complex is disrupted by the short hairpin RNA (shRNA)-mediated knockdown of GRP1 (Fig. 5g and Supplementary Fig. 6b ). Although depletion of GRP1 did not effect TMV shedding (Supplementary Fig. 6c ), it resulted in the release of TMVs with decreased Exportin-5 but not Dicer, Argonaute-2 ( Fig. 5h and Supplementary Fig. 6d ) or other known TMV protein cargoes (Supplementary Fig. 6e ). The loss of GRP1 did reduce TMV premiRNA and miRNA cargo (Fig. 5i,j and Supplementary Fig. 6f,g ) despite increasing their cellular levels ( Supplementary Fig. 6h,i) . Similar results were not seen with the knockdown of cytohesins 1 or 2-the other cytohesins known to act on ARF6 53 -where, despite a robust loss of the GEF, we found no change in the levels of Exportin-5 TMV cargo ( Supplementary Fig. 6j ).
The more favourable predicted binding energies together with the known role of ARF6-GTP in binding GRP1 and in relieving autoinhibition 54 suggested that, in addition to acting as a GEF, GRP1 might participate as a scaffold during Exportin-5 transfer from Ran-GTP to ARF6-GTP. We thus examined the impact of depleting GRP1 from cells with constitutive ARF6 activation. GRP1 silencing led to a significant loss of Exportin-5 as TMV cargo (Fig. 5k) . Furthermore, GRP1-shRNA led to a reduction of Exportin-5 coprecipitating with ARF6 (Fig. 5l) . Thus, GRP1 scaffolding facilitates the interaction between ARF6-GTP and Exportin-5, and the interaction between ARF6 and the ARF-GEF GRP1 is critical for the anterograde trafficking of Exportin-5 and pre-miRNA cargo inclusion in shed TMVs.
TMVs alter recipient cell behaviour in part through the transfer of miRNA cargo. Owing to their myriad bioactive cargoes, shed TMVs are capable of altering the behaviour in the surrounding cells 55 . To examine the effects of TMV-mediated miRNA transfer, we focused on miR-21 and utilized a combination of clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) and homology-directed repair (Fig. 6a) to disrupt its genomic locus. Puromycin selection rapidly killed most cells before the candidate condition rebounded (Fig. 6b) . Examination of the resulting cells revealed a population with significantly reduced miR-21 expression (Fig. 6c) and corresponding increase in known miR-21 target TIMP-3 (ref. 56 ; Fig. 6d ). To examine the TMV-mediated RNA transfer, we stained the TMV contents with the cell-permeant RNA dye SYTO RNAselect. The stained RNA was retained and distributed within recipient cells (Fig. 6e) . To monitor the miRNA-specific effects, we utilized miRNA sponge technology in which the 3ʹ untranslated region of destabilized GFP (dEGFP) contains miRNA binding sites to suppress translation 57 . Tumour-derived-microvesicle-transferred miR-21 effectively suppressed the translation of dEGFP, leading to a loss of protein at 10 h. Both GRP1-shRNA and miR-21 depletion blocked the loss of GFP protein (Fig. 6f) . The loss of GFP protein occurred despite no reduction in the levels of GFP mRNA at the early timepoint (Fig. 6g) . To examine the TMV-mediated effects in an endogenous system, we incubated BJ human foreskin fibroblast cells with LOX melanoma TMVs. Incubation with TMVs led to an increased expression of α-smooth muscle actin (SMA) in recipient cells (Fig. 6h) . To examine the miRNA-mediated effects, we examined the protein and mRNA levels of the miR-21 target SMAD-7 58 and found that TMV-mediated miR-21 transfer led to a loss of SMAD-7 protein and mRNA after 48 h, which was abrogated when shedding cells were depleted of GRP1 or miR-21 (Fig. 6i,j) . Together, these results highlight the functional consequences of TMV-mediated miRNA transfer downstream of GRP1 regulated trafficking.
Discussion
The formation and release of TMVs is a complex phenomenon with layered regulation governing TMV biogenesis and tightly controlling the specific inclusion or exclusion of bioactive cargo. The findings presented here describe the events involved in the regulated trafficking of pre-miRNA cargo to the sites of TMV biogenesis. This regulation occurs in part through the formation of a trafficking complex containing Exportin-5, pre-miRNA, ARF6 and a ARF GEF, GRP1. In our working model for pre-miRNA trafficking, we propose that ARF6-GTP-regulated phosphorylation of RanGAP1 allows for the transfer of cargo exported from the nucleus into the ARF6-regulated shuttling complex for anterograde movement (Supplementary Fig. 6k ). Furthermore, GRP1 serves as a scaffold facilitating the interaction between ARF6 and Exportin-5, which supports the argument that GEFs have functional roles beyond nucleotide exchange 59 . Although the mechanism outlined above results in the trafficking of the bulk of pre-miRNA cargo to TMVs, it does not exclude the possibility that further regulation may direct miRNA-processing machinery, or specific miRNA or pre-miRNA sequences into TMVs, as has been proposed for exosome miRNA and mRNA cargo 29, 30, 35 . The identification of CD43-regulated Dicer accumulation in cancer cell exosomes 14 , when combined with the results above showing differential regulation of pre-miRNA and Dicer trafficking, certainly suggests this. These regulatory layers highlight the significant consequences stemming from TMVmediated miRNA transfer, as it provides a mechanism for direct alterations of gene expression, without further processing, which allows for rapid cellular responses in recipient cells.
Disassembly of Ran-GTP/Exportin-5 export complexes requires RanBP1 and RanGAP1 for GTP hydrolysis and cargo liberation. A similar interaction facilitated by RanBP2 in vertebrate cells releases cargo, which is exported-through the interaction with Exportin-1 (Crm1)-into the cytosol 60 . This striking similarity certainly elevates the possibility that these are biologically redundant alternatives utilized to export cargo from the nucleus to the cytosol. However, our results suggest some level of specificity, as we found no change in the levels of TMV Exportin-1 when the pathway described above was inhibited. This could be due to both the soluble nature of RanGAP1 and RanBP1, and their high expression levels in tissue culture cells. A large proportion of Exportin-1 remains bound to the nuclear-pore complex following transportcomplex disassembly and GTP hydrolysis, possibly to enable rapid shuttling back to the nucleus. In light of the results presented here, it is tempting to speculate that it may also represent a level of cargo specificity with material that needs to traffic longer distances being exported via Exportin-5. Alternatively, the pathway outlined above may represent an intermediate level of trafficking regulation falling between sequence-specific targeting and the bulk movement of nuclear-associated cargo through the direct blebbing of the nuclear membrane 61 .
Research has suggested a global downregulation of miRNA in tumours 14, 20, 22 . Notably, the majority of studies aimed at understanding this phenomenon have focused on disrupted miRNA biogenesis. It is conceivable that miRNA downregulation may be due to their expulsion, along with their precursors, as TMV cargo. Literature reports suggest that miRNAs contained within EVs can influence gene expression in target cells [62] [63] [64] . The presence of mature miRNAs in TMVs underscores their propensity for manipulating normal tissues adjacent to the tumour-producing tumour-induced 'field No statistically significant relationships were found. h, BJ fibroblasts were incubated with purified LOX TMVs for 48 h and the levels of α-SMA were measured by western blotting using 20 μg of the cell lysates. Data presented as the mean ± s.d. for n = 3 biologically independent samples. i, SMAD-7 levels were measured using 20 μg of BJ-fibroblast cell lysate following treatment with isolated TMVs. Data are shown as the mean ± s.d. for n = 4 biologically independent experiments. j, The levels of SMAD-7 mRNA in TMV-treated BJ fibroblasts were measured by qRT-PCR as described in Methods. Data presented as the mean ± s.d. for n = 4 biologically independent experiments. P values were determined by multiple unpaired two-tailed Student's t-tests with Bonferroni correction (c,d,h), two-way ANOVA (g) or one-way ANOVA with Bonferroni correction (i,j). P < 0.05 was considered significant. The unprocessed blot images are shown in Supplementary Fig. 7 and the statistical source data in Supplementary Table 1 .
. Fluorophoreconjugated secondary antibodies (donkey anti-mouse FITC and donkey anti-rabbit TRITC) were purchased from Jackson Immunoresearch. Information on the use of the antibodies is contained in Supplementary Table 2. SecinH3 and TBB were purchased from Cayman Chemical.
shRNA. Short hairpin RNA against GRP1 (GRP1sh_1) was generated as previously published 67 . Briefly, a shRNA targeting GRP1 mRNA was subcloned into the lentiviral expression plasmid pLKO.1 using the following primer sequences: Fwd, 5 ′-CCGGGCATTAAGAACGAGCCATTTACTCGAGTAAATGGCTCG TTCTTAATGCTTTTTG-3′ and Rev, 5′-AATTCAAAAAGCATTAAG AACGAGCCATTTACTCGAG TAAATGGCTCGTTCTTAATGC-3′. The annealed oligos were further ligated between the AgeI and EcoRI sites of the pLKO.1 TRC-cloning vector. Positive clones were screened using EcoRI and NcoI double digestion and validated by sequencing. Additional MISSION shRNA constructs in the pLKO.1 background were purchased from SigmaAldrich (CYTH2:TRCN0000062100, CYTH1:TRCN0000062116 and CYTH3:TRCN0000179183).
Cell culture and transfection. LOX melanoma cells (a gift from O. Fodstad, Oslo University) were cultured in RPMI (RPMI-1640, Life Technologies) supplemented with 10% (v/v) EquaFetal serum (Atlas Biologicals), 2 mM l-glutamine and 100 U ml −1 penicillin-streptomycin (Life Technologies). LOX ARF6-GTP cells were similarly maintained with the addition of 200 µg ml −1 gentamycin and hygromycin-B selection reagents. OvCar3 cells were maintained in RPMI supplemented with 20% EquaFetal serum, 2 mM l-glutamine, 0.01 mg insulin and 100 U ml
penicillin-streptomycin. PC-3 cells were grown in F-12K (Life Technologies) with 10% EquaFetal serum and 100 U ml −1 penicillin-streptomycin. MDA-MB-231 cells were grown in RPMI (Life Technologies) supplemented with 1 mM sodium pyruvate (Gibco), 10% EquaFetal serum, 2 mM l-glutamine and 100 U ml −1 penicillin-streptomycin. 293FT (Thermo Fisher Scientific) cells were maintained in culture as per the manufacturer's specifications, including supplementation with 0.5 mg ml −1 Geneticin (Thermo Fisher Scientific). All cell lines were maintained in humidified incubators with 5% CO 2 . In some experiments, cells were pre-treated with 0.3 µM TBB (Cayman Chemical), 10 µM SecinH3 (Cayman Chemical), 50 µM chloroquine (Cell Signaling Technologies) or DMSO (Millipore Sigma) vehicle control for 6 h before media replacement and continued treatment for an additional 24 h. Where indicated, cells were transfected with the indicated plasmids using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Lipofectamine:DNA ratios of 3:1 were utilized and scaled based on the experimental needs; 1 µg of plasmid DNA was used for 2 × 10 5 cells. Cells were treated with 50 nM okadaic acid (Millipore Sigma) for 24 h to induce apoptosis.
Retro/lentiviral production and infection. 293FT cells (5 × 10 5 ) were plated in 10-cm dishes in complete growth media without antibiotics and allowed to adhere for 24 h, at which time the plating media was replaced with 5 ml of complete media without antibiotics. Transfection mix was prepared using 9 µg psPAX2, 3 µg pMD2.G, 3 µg lentiviral transfer plasmid and 36 µl Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. The cells were incubated overnight with transfection mix and the media was changed within 16 h. Complete media without antibiotics (10 ml) was added and the viral-conditioned media harvested 48 h post transfection. The supernatant was centrifuged at 3,000 r.p.m. for 15 min, filtered through 0.45-µm PVDF syringe filters, aliquoted and stored at −80 °C until use. To infect tumour cells, viral aliquots were thawed on ice, mixed 1:1 with tumour growth media without antibiotics and added to cells for 16 h. Polybrene was added to a final concentration of 8 µg µl −1 at the time of infection.
TMV isolation. The cells used for TMV isolation were plated and incubated to approximately 80% confluency at the time of conditioned media collection. Conditioned media was collected from the cells and the culture vessel was rinsed once with sterile PBS, which was subsequently added to the collected media. The mixture was then centrifuged for 15 min at 300g to remove cells and large debris. The supernatant was centrifuged for 20 min at 2,000g to pellet the apoptotic bodies. The TMVs were then isolated by centrifugation at 10,000g for 30 min. The resulting pellet was washed twice in sterile PBS and a final isolation was performed before downstream use.
RNA isolation and complementary DNA generation. The TMVs, isolated as described above, were incubated with 2 mg ml −1 RNase A (Qiagen) for 30 min at 37 °C in PBS before being re-isolated for RNA extraction. Small-RNA-enriched total RNA was isolated from TMVs using the miRvana miRNA isolation kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Isolated RNA was quantified using a NanoDrop 2000 (Thermo Fisher) to allow for input normalization in downstream applications. For mature miRNA analysis, 100 ng of isolated RNA was used as a template for a poly-A-tailing reaction and cDNA generation using the qScript microRNA cDNA synthesis kit (Quanta Bio). For pre-miRNA analysis, the cDNA synthesis method was adapted from previously published methods 68 . Briefly, a 15-μl reaction was assembled using 100 ng isolated RNA, 300 nM premiRNA specific primers and primers for the RNU6B internal control. The mixure was then incubated at 80 °C for 5 min to denature the input RNA followed by 5 min at 60 °C to anneal the primers and subsequently used for cDNA synthesis using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) according to the manufacturer's protocol. The pre-miRNA primer sequences were derived from previous research 68 : Pre-miR-21: F, 5′-GCTTATCAGACTGATGTTGACTG-3′ and R, 5′-CAGCCCATCGACTGGTG-3′; Pre-miR-27a: F, 5′-GCAGGGCTTAGCT GCTTG-3′ and R, 5′-GGCGGAACTTAGCCACTGT-3′; Pre-miR-100: F, 5′-AACCC GTAGATCCGAACTTG-3′ and R, 5′-TACCTATAGATACAAGCTTGTGCG-3′; Pre-miR-151: F, 5′-CTCGAGGAGCTCACAGTCTAG-3′ and R, 5′-GTCCTC AAGGAGCTTCAGTC-3′; and RNU6B: F, 5′-CTCGCTTCGGCAGCACA-3′ and R, 5′-AACGCTTCACGAATTTGCGT-3′.
TMV miRNA Bioanalyzer analysis and sequencing. Bioanalyzer small-RNA analysis was carried out using the RNA 6000 nano kit or the Small RNA analysis kit on a 2100 Bioanalyzer Instrument (Agilent Technologies). For TMV miRNA sequencing, small-RNA libraries were generated using the NEBNext small RNA library prep set for Illumina (New England BioLabs) followed by deep sequencing using the HiSeq 2500 (Illumina) platform. After the removal of the adaptor sequences, sequencing data were mapped to a Homo sapiens miRNA sequence file collected from miRBase V21 for annotation using Bowtie2 and Samtools. Heat-map comparisons of the levels of the 50 most-abundant miRNAs in LOX TMVs and LOX-ARF6-GTP TMVs were performed using R library EdgeR after normalization by library size. R library gplots was then used to generate a heat-map plot.
qRT-PCR. Quantitative PCR with reverse transcription was performed on a
Step-One-Plus real-time PCR machine (Applied Biosystems) and analysed using the comparative C T method. Amplification was monitored using a PerfeCTa SYBR Green SuperMix with ROX (Quanta Bio). Analysis of the TMV miRNA levels was performed using the following miR-specific primers purchased from Quanta Bio: hsa-miR-21-5p HSMIR-0021-5P, hsa-miR-100-5p HSMIR-0100-5P, hsa-miR27a-3p HSMIR-0027A-3P and hsa-miR-151a-3p HSMIR-0151A-3P. Pre-miRNA levels were analysed using the same workflow with the primers listed above. To determine miR-21 knockdown, qRT-PCR was carried out as described earlier using a Taqman probe (Hs04231424_s1) from Thermo Fisher. The levels of EGFP (Mr04097229_mr) and SMAD-7 (Hs00998193_m1) were measured using the Fast Advanced Cells to C T kit from Thermo Fisher. All Taqman assays used 18S ribosomal RNA (Hs99999901_s1) as an input control and were cycled according to the manufacturer's instructions.
Immunofluorescence. Cells were plated on glass coverslips and TMVs were plated on poly-l-lysine coated coverslips, and allowed to adhere for a minimum of 18 h before being fixed in 4% paraformaldehyde (Electron Microscopy Supply). The fixed cells were washed three times with filtered 1×PBS, pre-permeabilized with 1×PBS + 0.3% Triton X-100, blocked and permeabilized in 5% BSA, 0.2% Triton X-100 and 0.05% Tween-20 in 1×PBS, and incubated with primary antibodies diluted in blocking buffer as indicated in the figures. The cells were then incubated with fluorophore-conjugated secondary antibodies together with rhodaminephalloidin and ToPro-3 iodide (Life Technologies) and mounted using anti-fade gold mounting media (Life Technologies).
Scanning electron microscopy. Cells, isolated TMVs and isolated exosomes were incubated overnight in naive EV-free culture media. For EV fractions, the coverslips were first coated in poly-l-lysine (0.1% w/v). The samples were fixed in 2% electron-microscopy-grade glutaraldehyde (Electron Microscopy Sciences) diluted in SEM buffer (0.1 M sodium cacodylate, pH 7.5) for 1 h at room temperature. The samples were rinsed (3 × 10 min) in SEM buffer before further fixation with 1% osmium tetroxide in SEM buffer for 1 h at room temperature. Following a second rinsing step (3 × 10 min) in fresh SEM buffer, the samples were taken through a series of dehydration rinses in 50%, 70%, 80%, 95% and 100% electron-microscopy-grade ethanol, with each step consisting of two 10-min incubations. Samples in 100% ethanol were subjected to critical-point drying by replacing ethanol with 100% liquid CO 2 and bringing the CO 2 to its critical point. The dried coverslips were mounted to SEM stubs (Ted Pella Inc.) using carbon tape and conductive silver paste. The samples were sputter coated with iridium to a thickness of 4 nm and imaged using a Magellan 400 (FEI) scanning electron microscope.
Immunoprecipitations and western blotting. For western blotting, cells were lysed in buffer containing 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 20 mM Tris-HCl pH 7.5 and 1% Triton X-100 (all purchased from VWR). Just before use, mammalian protease inhibitor cocktail (Millipore Sigma) was added to complete the buffer. Triton-insoluble fractions were removed by centrifugation at 15,000g for 15 min. The lysates were then ready for use in downstream applications. For the immunoprecipitation experiments, cells were first lysed in Co-IP buffer containing 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 20 mM KCl, 1.5 mM MgCl 2 and 0.5% Triton X-100. Just before use, mammalian protease inhibitor cocktail (Millipore Sigma) was added to complete the buffer. Insoluble fractions were removed by centrifugation as described above before being pre-cleared by incubation with Protein A/G Plus agarose beads (Santa Cruz Biotechnology) for 1 h at 4 °C with gentle inversion. Pre-cleared lysates containing 200 µg total protein were subsequently transferred to new tubes for overnight antibody incubation at 4 °C with gentle inversion. Fresh Protein A/G Plus beads were added to the antibody mix and inverted for 1 h at 4 °C. The beads were pelleted by centrifugation at 300g for 2 min, the supernatant was removed and 1 ml fresh lysis buffer was added. This was repeated for a total of three washes. Following the washing step, beads were resuspended in 1×SDS loading dye and incubated in a boiling water bath for 6 min before being separated by SDS-PAGE. The PAGE gels were then transferred to a PDVF membrane (Millipore Sigma). Non-specific binding was blocked by incubation in 5% non-fat milk in TBS + 0.05% Tween-20 for 1 h at room temperature. Primary-antibody incubation was carried out based on the manufacturer's recommendations. Haemagglutinin immunoprecipitations were carried out using the Protein G Dynabead immunoprecipitation kit from Thermo Fisher. The cells were lysed as described above before following the workflow outlined by the bead manufacturer.
ARF6-GTP pulldown. The pGEX4T-MT2 plasmid was described previously 66 . Recombinant GST-MT2 was expressed in Escherichia coli and conjugated to glutathione high capacity magnetic agarose beads (Millipore Sigma) according to the manufacturer's instructions. LOX or LOX-ARF6-Q67L cells in log phase growth were lysed in MT2 assay buffer (50 mM Tris-HCl pH 7.4, 500 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS, with mammalian protease inhibitor added just before use). Triton-insoluble fractions were removed by centrifugation at 15,000g for 15 min. For each pulldown assay, a 50-μl aliquot of the GST-MT2 fusion-conjugated glutathione beads was washed three times with lysis buffer and incubated with 100 µg of lysate in 200 µl of complete lysis buffer with 2 mM ZnCl 2 for 1 h at 4 °C with inversion. The beads were collected and washed three times with wash buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1% Triton X-100, 2 mM ZnCl 2 and protease inhibitor). The bound proteins were eluted by boiling for 7 min in 1×SDS loading buffer and subjected to SDS-PAGE and western blotting.
In vitro ARF6-Exportin-5 pulldown. The pGEX-3X GST-WT-ARF6 plasmid was described previously. Recombinant ARF6 protein was conjugated to glutathione high capacity magnetic agarose beads according to the manufacturer's instructions. LOX cells, grown to 80% confluency, were lysed in co-immunoprecipitation buffer (described above) for 15 min at 4 °C and detergent-insoluble fractions were removed by centrifugation at 15,000g for 15 min. While lysing cells, 50 µl of 50% bead slurry per sample were blocked in lysis buffer with 5% BSA for 10 min at 4 °C with gentle inversion. Following blocking, the beads were rinsed twice with lysis buffer. Total protein (400 µg) in pre-cleared lysates (diluted as needed to 1 µg µl −1 with additional lysis buffer) was added to the blocked beads together with 100 µM GTP-γ−S, 1 mM GDP, or vehicle control for 60 min at 37 °C. Following protein binding, the beads were washed 3× with 1 ml ice-cold lysis buffer, resuspended in 1×SDS sample buffer, boiled for 5 min, separated by SDS-PAGE and probed by western blotting.
RNA immunoprecipitation. LOX cells were cultured in complete EV-free media for 72 h before TMV isolation. The isolation of TMVs was carried out as described above. Isolated TMVs were resuspended in sterile filtered PBS and incubated with 2 mg ml −1 RNase A (Qiagen) for 30 min at 37 °C before being re-isolated and lysed in RIP buffer consisting of 150 mM KCl, 25 mM Tris pH 7.4, 5 mM EDTA, 0.5 mM dithiothreitol, 0.5% Triton X-100 with protease inhibitor cocktail and 100 U ml −1 RNAase inhibitor SUPERase (Life Technologies) added immediately before use. The insoluble fraction was removed by centrifugation at 18,000g for 15 min and the supernatant was transferred to a new tube. Protein A/G Plus Agarose (Santa Cruz Biotechnology) bead slurry was added to the lysate (1:5 v/v) and the mixture was incubated at 4 °C for 1 h with inversion. The beads were removed and the lysates were subsequently divided (input, IgG immunoprecipitation and Exportin-5 immunoprecipitation) and incubated with antibody overnight at 4 °C with gentle inversion before incubation with new Protein A/G Plus Agarose slurry for 1 h. The beads were washed three times with fresh lysis buffer. After the third wash, the beads were resuspended in 1 ml fresh lysis buffer and 10% was removed to validate immunoprecipitation by western blotting as described above. The RIP beads were then washed once in sterile filtered PBS + SUPERase and protease inhibitor cocktail before being resuspended in cold Trizol. RNA was extracted following the manufacturer's protocol. Precipitated RNA was then analysed by PCR as described above. The PCR products were separated on 5% non-denaturing TBE-PAGE gels, stained with ethidium bromide and the bands were imaged.
CRISPR-Cas9-mediated mir-21 knockdown. Guide RNA sequence targeting miR-21 (5′-CACCGCTCATGGCAACACCAGTCGA-3′) was selected from the GECKO library and cloned into the pSpCas9(BB)-2A-GFP (PX458) plasmid, a gift from F. Zhang (Addgene plasmid no. 48138; http://n2t.net/addgene:48138; RRID:Addgene_48138) as previously published 69 . The homology-directed repair plasmid was based on PL552, a gift from S.-C. Zhang (Addgene plasmid no. 68407; http://n2t.net/addgene:68407; RRID:Addgene_68407). Genomic DNA was isolated from exponentially growing LOX cells using the QIAamp DNA mini kit (Qiagen) and eluted into nuclease-free water. The 5′-and 3′-flanking regions of the miR-21 genomic locus were amplified by PCR using Phusion high-fidelity polymerase (Thermo Fisher) with the following primer pairs: miR-21-L-Kpn1-5.1 5′-GGCCAGTGAAGGTACCGTCTTACAAGTGAGCTGACACC-3′, miR-21-LSal1-3.1 5′-CACTGTAGAGGTACCGACATGGTGGAGTCGACTACTAC-3′, miR-21-R-BamH1-5.2 5′-CATTATACGGATCCATTTTGGTATCTTTCATCT GACCATC-3′ and miR-21-R-NotI-3.2 5′-TATCACCGGGCGGCCGCCAAG AAAGGAAGGCACGAACAG-3′, which were modified from previously published reports 69 . The PCR products were cloned sequentially between the KpnI and SalI sites, and BamHI and NotI sites to generate pL552-miR-21. LOX cells were cotransfected with PX458 together with pL552-miR-21 using Lipofectamine 2000 (Thermo Fisher). The transfected cells were grown for five days before being selected with 400 ng ml −1 puromycin. The resulting colonies were screened for miR-21 levels using qRT-PCR.
Nanoparticle tracking analysis. Conditioned media or TMVs were isolated from cells as described above. Tumour-derived microvesicles were resuspended in filtered PBS and injected into a NanoSight LM10 equipped with a 488-nm laser. Particles were tracked for 90 s and tracking analysis was carried out using NanoSight nanoparticle tracking analysis software. Particles in suspension scatter a laser beam passing through the sample chamber in such a manner that they can easily be visualized at ×20 magnification. The attached scientific CMOS camera captures a video file of the particles moving under Brownian motion. The software subsequently tracks many individual particles, estimating their hydrodynamic diameters using the Stokes-Einstein equation.
TMV-mediated miRNA transfer. TMVs were isolated as described above, resuspended in filtered PBS and quantified using nanoparticle tracking analysis. Equal numbers of TMVs, at a ratio of 50:1 (Fig. 6f,g ) or 25:1 (Fig. 6e,h-j) to recipient cells, were pelleted and resuspended in naive EV-free cell culture media and added to the recipient cells in culture. The cells were incubated for 10 ( Fig. 6f,g ) or 48 h (Fig. 6e ,h-j) before use in downstream experiments. The cells were replenished with additional TMVs at t = 24 h in the 48-h experiments. To stain endogenous RNA, TMVs or PBS vehicle control were stained in 500 nM SYTO RNAselect for 30 min at 37 °C. The stained TMVs were washed extensively in fresh filtered PBS before being resuspended in naïve EV-free cell culture media.
Statistics and reproducibility. Statistical analyses were performed using GraphPad Prism 6.0f or Microsoft Excel version 16.12. A Student's t-test was used when comparing two groups with data that seemed to be normally distributed with similar variances. When comparing multiple treatment groups to a single control and the data were normally distributed, a Bonferonni correction for multiple comparisons was employed. When multiple groups were analysed and each group was compared with all other groups, and the data were normally distributed, we performed a one-way ANOVA with Sidak's multiple comparisons correction. No outliers were excluded from analysis and all experiments were performed on at least three biological replicates under similar conditions. Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
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